Biogen Canada is deeply disappointed for the SMA community due to the draft recommendation from the Canadian Agency for Drugs and Technologies in Health (CADTH) that has advised against SPINRAZATM (nusinersen) reimbursement for adult patients with spinal muscular atrophy (SMA)1. SPINRAZATM, approved in Canada in 2017 as the first treatment for SMA, has been widely used and reimbursed by multiple provinces for patients under 18 as well as for patients of all ages in Quebec.
Pioneers in Neuroscience
Draft CADTH Recommendation for SPINRAZATM (nusinersen) Fails Adults in Need of Treatment for Spinal Muscular Atrophy (SMA)
Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (Ranibizumab)
BYOOVIZ™ becomes the first Lucentis® biosimilar to be approved in Canada following its approval in Europe and the United States in 2021
Biogen Canada Welcomes Eric Tse as New General Manager in New Toronto Head Office
Biogen Canada Inc. is pleased to announce Eric Tse has been named as its new General Manager, responsible for leading the company’s operations in Canada.
Biogen today, announced plans to initiate a global Phase 3b clinical study, ASCEND. The ASCEND study is designed to evaluate the clinical outcomes and assess the safety of a higher dose of SPINRAZA™ in children, teens and adults with later-onset spinal muscular atrophy (SMA) following treatment with Evrysdi® (risdiplam).
Biogen Canada receives Top 50 Best Workplaces™ in Canada and Best Workplaces™ for Women
Biogen Canada Inc. is exceptionally proud to announce that it has been recognized as one of the “Top 50 Best Workplaces™” in Canada and has also been named one of the “Top 50 Best Workplaces™ for Women” in Canada.
Biogen Canada recognized as a Great Place to Work® and one of the 2020 Best Workplaces™ in Healthcare
Biogen Canada is proud to announce that it has been certified as a Great Place to Work® (GPTW) and named to the 2020 list of Best WorkplacesTM in Healthcare.
Biogen Canada investment in newborn screening study underlines commitment to research in spinal muscular atrophy (SMA)
Time is of the essence when it comes to preserving motor neuron function in SMA. Early diagnosis and management of this debilitating neurodegenerative condition which is the leading cause of genetic death in infants is crucial. We are proud to have contributed to the newborn screening pilot study at CHEO to lay the groundwork for adding SMA to routine newborn screening panels.
Further Together in SMA
SMA Awareness Month is a time for the entire SMA community to come together and raise awareness to improve outcomes for patients across Canada.
COVID-19 Update
Stepping up to support Canadian communities during the COVID-19 pandemic
The impact of the COVID-19 pandemic is being felt around the world and by so many. More than ever, our communities need us and are counting on our support. This is the rationale behind the Biogen Foundation $10M global commitment to address the immediate needs of communities and hospital systems.
COVID-19 Update
TO PATIENTS, HEALTHCARE PROVIDERS, PARTNERS, AND OUR COMMUNITY
As the novel coronavirus (COVID-19) outbreak evolves in Canada and around the world, the health and safety of all those who are impacted in any way is our utmost concern.
Biogen Canada Inc.
3250 Bloor Street West
East Tower, Suite 1200
Toronto ON, M8X 2X9
General Information
Phone: +1 866 359 2502 or +1 416 234 7999
Fax: +1 416 234 7849
Email: CanadaGeneral.Mailbox@biogen.com
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
Working at Biogen Canada
We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you.
Explore disease areas:
Learn more about Biogen on our global site